Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide

References

• Brandes A. Behandling af atrieflimren. Rationel Farmakologi Månedsblad, 2008. http://www.irf.dk/dk/publikationer/rationel_farmakoterapi/maanedsblad/2008/behandling_af_atrieflimren.htm. Accessed October 2, 2012
   Google Scholar
• Lip GYH, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648-61
   Google Scholar
• Working Party of Dansk Selskab for Apopleksi. Referenceprogram for behandling af patienter med apopleksi. Copenhagen: Dansk selskab for Apopleksi, 2009
   Google Scholar
• Boos CJ, More RS. Current controlled trials in anticoagulation for non-valvular atrial aibrillation – towards a new beginning with ximelagatran. Curr Contr Trials Cardiovasc Med 2004;5:1-7
   Google Scholar
• Schwartz NE, Albers GW. Dabigatran challenges warfarin’s superiority for stroke prevention in atrial fibrillation. Stroke; J Cerebral Circulation 2010;41:1307-9
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. N Eng J Med 2009;361:1139-202
   Google Scholar
• Lægemiddelstyrelsen. Trends i salget af apoteksforbeholdt medicin – Udviklingen i 4. kvartal 2011. 2012. http://www.ssi.dk/Sundhedsdataogit/Analyser%20og%20rapporter/Trends%20i%20salget%20af%20apoteksforbeholdt%20medicin/∼/media/Indhold/DK%20-%20dansk/Sundhedsdata%20og%20it/NSF/Analyser%20og%20rapporter/Trends%20i%20salget%20af%20apoteksforbeholdt%20medicin/4_2011.ashx. Accessed December 6, 2012
   Google Scholar
• Evers S, Goossens M, De Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus. Int J Technol Assess Health Care 2005;21:240-5
   PubMed Web of Science ®Google Scholar
• Phillip B, Ball C, Badenoch D, et al. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). Oxford Centre for Evidence-based Medicine 2009. http://www.cebm.net/index.aspx?o=1025. Accessed December 6, 2012
   Google Scholar
• Hamberg-van Reenen HH, Proper KI, Van den Berg M. Worksite mental health interventions: a systematic review of economic evaluations. Occup Environ Med 2012; published online 3 August 2012, doi: 10.1136/oemed-2012-100668
   Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011, published online 4 March 2011;123:2562-70
   Google Scholar
• You JHS, Tsui KKN, Wong RSM, et al. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PloS One 2012;7:e39640
   Google Scholar
• Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-8
   Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemostasis 2011;106:753-992
   Google Scholar
• Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. Br Med J 2011;343:d6333
   Google Scholar
• Langkilde LK, Bergholdt Asmussen M, Overgaard M. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ 2012;15:695-703
   Google Scholar
• Davidson T, Husberg M, Janzon M, et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J 2012;34:177-83
   Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
   PubMed Web of Science ®Google Scholar
• Kamel H, Johnston SC, Easton JD, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke J Cerebral Circulation 2012;43:881-3
   Google Scholar
• González-Juanatey JR, Álvarez-Sabin J, Lobos JM, et al. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Rev Esp Cardiol (English Edition) 2012;65:901-10
   Google Scholar
• Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-47
   Google Scholar